Pan-drug-resistant (PDR)Acinetobacter baumannii is an important nosocomial pathogen that poses therapeutic challenges. Tigecycline alone or in combination with agents such as colestimethate, imipenem, and/or amikacin is being used clinically to treat PDR A. baumannii infections. The purpose of this study was to compare in vitro susceptibility testing by epsilometric (Etest) methods and the checkerboard (CB) method with testing by time-kill analysis. PDR A. baumannii clinical strains representing eight unique pulsed-field gel electrophoresis clones selected from a total of 32 isolates were tested in vitro with tigecycline, colestimethate, imipenem, and amikacin in single-and two-drug combinations by using two different methods of Etest (with a fixed ratio method [method 1] and with the incorporation of the active drug in medium [method 2]) and by using CB. The three-drug combination of imipenem, tigecycline, and amikacin was also tested by CB. These results were compared to time-kill results. Synergy was consistently detected with the imipenem plus colestimethate and tigecycline plus imipenem combinations. The Etest method with active drug incorporated into the agar allowed us to detect synergy even in the presence of the active drug and was more comparable to CB and time-kill tests. Synergy was detected with the three-drug combination of imipenem, tigecycline, and amikacin by both CB and time-kill methods among several tested clones. These findings indicate the utility of synergy testing to predict activity of specific antibiotic combinations against PDR A. baumannii.In recent years Acinetobacter baumannii, an aerobic, Gramnegative coccobacillus, has emerged as an important nosocomial pathogen due to multiple drug resistance mechanisms, and it can be an extremely difficult microorganism for the clinician to treat (3,8,20,22). It causes a variety of infections that include pneumonia, wound, urinary tract, bloodstream, and intra-abdominal infections (3,8). We had experienced an increased number of cases of A. baumannii with resistant or intermediate susceptibility patterns to carbapenems over a 2-year time frame at our medical center. Growing numbers of isolates locally, nationally, and internationally have shown resistance to antibiotics such as the carbapenems, which previously had excellent activity in vitro and clinically. Our annual medical center antibiograms and a review of the literature (1,9,10,12,20,22,23,25,26) support this. Nontraditional agents, such as colestimethate (polymyxin E) and polymyxin B, despite the associated high toxicities, are being used to treat patients infected with pan-drug-resistant (PDR) A. baumannii (with pan-drug resistance defined as resistance to all routinely tested antimicrobials including carbapenems). Antibiotic resistance has also developed among some strains during treatment with these agents (10,20). Drug treatment with newer antimicrobials or antimicrobial combinations has become increasingly important to eradicate these infections.Tigecycline was approved by the Food ...

Rapid organism detection of Staphylococcus aureus bacteremia and communication to clinicians expedites antibiotic optimization. We evaluated clinical and economic outcomes of a rapid polymerase chain reaction methicillin‐resistant S. aureus/S. aureus blood culture test (rPCR). This single‐center study compared inpatients with S. aureus bacteremia admitted from 1 September 2008 through 31 December 2008 (pre‐rPCR) and those admitted from 10 March 2009 through 30 June 2009 (post‐rPCR). An infectious diseases pharmacist was contacted with results of the rPCR; effective antibiotics and an infectious diseases consult were recommended. Multivariable regression assessed clinical and economic outcomes of the 156 patients. Mean time to switch from empiric vancomycin to cefazolin or nafcillin in patients with methicillin‐susceptible S. aureus bacteremia was 1.7 days shorter post‐rPCR (P = .002). In the post‐rPCR methicillin‐susceptible and methicillin‐resistant S. aureus groups, the mean length of stay was 6.2 days shorter (P = .07) and the mean hospital costs were $21,387 less (P = .02). rPCR allows rapid differentiation of S. aureus bacteremia, enabling timely, effective therapy and is associated with decreased length of stay and health care costs.

Little is known about the epidemiology and mode of transmission of the agent of human granulocytic ehrlichiosis (HGE). Analyses of an engorged female Ixodes dammini tick removed from an HGE patient and 101 field-collected I. dammini and Dermacentor variabilis from three Wisconsin counties for Borrelia burgdorferi and Ehrlichia phagocytophila/Ehrlichia equi DNA revealed that the patient tick and 7 of 68 I. dammini ticks from Washburn County collected in 1982 and 1991 were positive for ehrlichial DNA; 10 ticks from the same collections were positive for B. burgdorferi. Two specimens (2.2%) were positive for both organisms. Serologic evidence for exposure to the agent of HGE or its relatives was detected in 3 of 25 Lyme disease patients from the upper Midwest. These data argue that I. dammini is a common vector for transmission of both Lyme disease and HGE.